Q5166 Denosumab-desu - CanMED: HCPCS

Return Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Denosumab-desu

Brand Name:

Jubereq, Osvyrti

Strength:

1mg

HCPCS:

Q5166

SEER*Rx Category:

Immunotherapy

Major Drug Class:

Monoclonal Antibody

Minor Drug Class:

RANKL

Oral (Y/N):

No

FDA Approval Year:

2026

FDA Discontinuation Year:

CMS Effective Date:

June 17, 2026

CMS Discontinuation Date:

Status:

In Use